Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

HER2-Positive Breast Cancer Moves Toward Right-Sized Therapy

A Nature Reviews Clinical Oncology review examines how HER2-positive breast cancer treatment is shifting toward risk-adapted use of T-DXd, maintenance therapy and biomarkers.

By Dr. Revathy Mohan V.R., MBBS · Oct 19, 2026 · 6 min read

Oncology·Nat Rev Onc

ADC biomarker strategy needs to move beyond target expression

A Nature Reviews framework argues ADC biomarkers must capture antigen biology, payload susceptibility, and toxicity to improve selection…

Oct 19, 2026

Oncology·BMJ Open

Breast cancer remission consultation appears feasible and improves quality of life

A one-hour remission consultation after localized breast cancer was accepted by most patients and was linked to better…

Oct 19, 2026

Oncology·Front Immunol

Melanoma m5C study links NSUN5-YBX1-CENPF program to immune resistance

A melanoma study maps an m5C-linked NSUN5-YBX1-CENPF program to proliferation, immune resistance signals, and treatment-associated transcriptomic shifts.

Oct 19, 2026

Oncology·JAMA Open

Vaginal Laser Therapy for GSM in Breast Cancer Survivors Falls Short on Proof

A modality-specific review found low-certainty evidence for vaginal laser therapy in breast cancer survivors, with no direct proof…

Oct 19, 2026

Oncology·JAMA Open

Rectal Cancer iTNT: Organ Preservation Preserves QoL and Bowel Function

Long-term follow-up after immunotherapy-based total neoadjuvant therapy found organ preservation linked to better QoL and anorectal function than…

Oct 19, 2026

Oncology·Cancer Disc

Clear Cell Renal Cell Carcinoma Study Links lncRNA Axis to OXPHOS Rewiring

AACR abstract describes a germline-encoded lncRNA-mitochondrial axis that alters oxidative phosphorylation in clear cell renal cell carcinoma.

Oct 19, 2026

Oncology·Cancer Disc

RET inhibitor failure in metastatic lung cancer: Real-world outcomes after progression

A real-world RET-MAP registry analysis examines second- and third-line treatment outcomes after selective RET inhibitor failure in RET…

Oct 19, 2026

Oncology·Gut

IRF1 Shapes Metabolism and Immune Programs in Low-Grade Pancreatic Cancer

IRF1 drives immune and metabolic programs in low-grade pancreatic cancer cells, linking differentiation status to antigen presentation and…

Oct 19, 2026

Oncology·JNCI

FFPE Storage Can Harm NGS Quality, JNCI Correction Notes

JNCI issued a correction on FFPE tissue storage and next-generation sequencing, with emphasis on DNA damage and enzyme-based…

Oct 19, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.